The app is a useful screening tool for the most common retinal diseases such as diabetic macula edema, exudative macular degeneration, retinal vein occlusion macula edema, central serous chorioretinopathy, and macula-off retinal detachments.
Dr. Stephen G. Odaibo, RETINA-AI’s founder, CEO, and Chief Software Architect, states that the development and release of the Android app solidifies the company’s technological capability in the mobile health sector. “Earlier this year RETINA-AI broke ground by developing and releasing the world’s first mobile AI app for eye care providers. That was the iOS version. Now by adding the Android we have demonstrated full spectrum technological capability to develop and deliver mobile AI products in healthcare.”
RETINA-AI is sponsoring the DATUM alpha study, a multicenter retrospective image analysis validation study of Fluid Intelligence. DATUM stands for Diagnostic mobile Artificial intelligence Technology for detecting fluid Underneath and Inside the Macula. In the study, Retina Specialists, that is Board-Certified ophthalmologists who have fellowship training in retina, compare their assessment of OCTs to the assessment of the AI app. Initial results are in press and show a sensitivity of 90% and a specificity of 82.5%. More studies will follow DATUM as RETINA-AI continues to develop and train AI algorithms. In addition to clinical studies, RETINA-AI has multiple AI diagnostic healthcare software products in the pipeline.
“One of RETINA-AI’s strengths is a unique vertical understanding of the ophthalmic space coupled with engineering expertise and delivery experience” says Odaibo who is himself a retina specialist, board-certified ophthalmologist, and full stack AI engineer. Odaibo is the only ophthalmologist in the world with advanced degrees in both Mathematics and Computer Science. He attended medical school at Duke University, ophthalmology residency at Howard University, and retina fellowship at the University of Michigan Ann Arbor. He got his M.S. in Mathematics at UAB and M.S. in Computer Science at Duke.
“We thank God for the tremendously unique opportunity we have as a company to revolutionize the field of ophthalmology. No one else in the world is able to do what we are doing.”
RETINA-AI is harnessing the power of AI to improve patient care both in the U.S. and globally. The company is currently raising equity capital to accelerate its technological innovation leadership in the healthcare AI space.